Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 43.6 mg - capsule, hard - excipient ingredients: sodium starch glycollate type b; titanium dioxide; indigo carmine; lactose monohydrate; purified water; macrogol 6000; ammonium chloride; sucrose; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ziprasidone hydrochloride, quantity: 21.8 mg - capsule, hard - excipient ingredients: gelatin; lactose monohydrate; sodium starch glycollate type b; purified water; sucrose; titanium dioxide; ammonium chloride; sodium lauryl sulfate; indigo carmine; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ziprasidone is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy. ziprasidone is indicated as monotherapy for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 1.026 g (equivalent: vancomycin, qty 1 g) - injection, powder for - excipient ingredients: nitrogen; hydrochloric acid; water for injections - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 513 mg (equivalent: vancomycin, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; water for injections; nitrogen - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet - excipient ingredients: hyprolose; sodium citrate; crospovidone; magnesium stearate; mannitol; pregelatinised maize starch; colloidal anhydrous silica - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: crospovidone; colloidal anhydrous silica; mannitol; sodium citrate; pregelatinised maize starch; hyprolose; magnesium stearate - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; pregelatinised maize starch; sodium citrate; mannitol - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - alpha-cypermethrin; liquid hydrocarbon - emulsifiable concentrate - alpha-cypermethrin pyrethroid active 100.0 g/l; liquid hydrocarbon solvent other 760.0 g/l - insecticide - apple | apricot | asparagus - except white asparagus | banksia | broccoli | brussels sprouts | cabbage | canola | cauliflower | - aphids - rhopalosiphum spp. | apple dimpling bug - c. liebknechti | apple weevil | autumn gum moth | banksia moth - danima banksiae | blackheaded pasture cockchafer | blue oat or pea mite | bronzed field beetle | brown pasture looper | cabbage moth | cabbage white butterfly | cadmus spp. | cluster caterpillar | common armyworm - mythimna convecta | corn earworm | cotton budworm or bollworm | cutworm - agrotis spp. | eucalyptus weevil | garden or south african vine weevil | green mirid bug | grey cluster bug | helicoverpa armigera | helicoverpa spp. | liparetrus spp. - adults | native budworm or bollworm | pasture webworm - hednota spp. | pea weevil | pink or brown cutworm | plague thrips | redlegged earth mite | rice bloodworm | rough bollworm | rutherglen bug | sorghum midge | southern or barley armyworm | tasmanian eucalyptus leaf beetle | tobacco budworm | tobacco looper or looper caterpillar | tomato grub | vegetable weevil | wingless grasshopper | acrossidius tasmaniae | barley armyworm | barley grub | b

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcium carbonate,risedronate sodium -

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 40 mg in 1 ml - lidocaine hydrochloride is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. lidocaine hydrochloride is contraindicated in patients with a known hypersensitivity either to local anesthetics of the amide type or to the components of the topical solution.